M
Massimo De Luca
Researcher at Seconda Università degli Studi di Napoli
Publications - 20
Citations - 667
Massimo De Luca is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cirrhosis & Ribavirin. The author has an hindex of 9, co-authored 19 publications receiving 590 citations.
Papers
More filters
Journal ArticleDOI
Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation
F.P. Picciotto,Giovanni Tritto,Alfonso Galeota Lanza,Luigi Addario,Massimo De Luca,Giovan Giuseppe Di Costanzo,F. Lampasi,Maria Teresa Tartaglione,Giuseppina Marino Marsilia,Fulvio Calise,O. Cuomo,Antonio Ascione +11 more
TL;DR: Responsibility rate to antiviral therapy in HCV reinfection after liver transplantation is higher if a full dose of antiviral drugs is administered and if treatment starts before histological cirrhosis has developed, which improves patient survival.
Journal ArticleDOI
Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection
Antonio Ascione,Massimo De Luca,Maria Teresa Tartaglione,F. Lampasi,Giovan Giuseppe Di Costanzo,Alfonso Galeota Lanza,F.P. Picciotto,Giuseppina Marino Marsilia,Luca Fontanella,Gioacchino Leandro +9 more
TL;DR: In patients with chronic HCV infection, peginterferon alfa-2a plus ribavirin produced a significantly higher sustained virological response (SVR) rate than pegin terferonAlfa- 2b plus Ribavirin.
Journal ArticleDOI
Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial.
Giovan Giuseppe Di Costanzo,Raffaella Tortora,Giuseppe D'Adamo,Massimo De Luca,F. Lampasi,Luigi Addario,A. Lanza,F.P. Picciotto,Maria Teresa Tartaglione,G. Cordone,Michele Imparato,Silvana Mattera,Claudio Maurizio Pacella +12 more
TL;DR: A non‐inferiority randomized trial comparing RFA with LA in patients with cirrhosis and HCC within Milan criteria is performed.
Journal ArticleDOI
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
Luca Rinaldi,Alessandro Perrella,Maria Guarino,Massimo De Luca,Guido Piai,Nicola Coppola,Pia Clara Pafundi,Fortunato Ciardiello,Morena Fasano,Erika Martinelli,Giovanna Valente,Riccardo Nevola,Caterina Monari,Lucia Miglioresi,Barbara Guerrera,Massimiliano Berretta,Ferdinando Carlo Sasso,Filomena Morisco,Antonio Izzi,Luigi Elio Adinolfi +19 more
TL;DR: The data suggest that early HCC occurrence appears more frequently related to Sofosbuvir-based therapy without Ribavirin which, indeed, seems to play a protective role on HCC onset, and a careful follow-up should be mandatory, especially in those regimens including SofosBuvir without Ribvirin.
Journal ArticleDOI
Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years.
TL;DR: Age‐standardized death rate (ASDR) can serve as an indirect assessment of the burden of Cirrhosis and HCC in Europe because epidemiological data on these diseases are scarce.